Education
About Us
Working with TipRanks
Follow Us
Cybin (CYBN)
:CYBN
CYBN Stock Chart & Stats
$5.99
-$0.47(-4.69%)
At close: 4:00 PM EST
$5.99
-$0.47(-4.69%)
Day’s Range― - ―
52-Week Range$4.81 - $10.80
Previous Close$9.5
Volume184.55K
Average Volume (3M)657.06K
Market Cap
$1.39M
Enterprise ValueN/A
Total Cash (Recent Filing)$118.69M
Total Debt (Recent Filing)$44.50M
Price to Earnings (P/E)―
Beta0.87
Next Earnings
Feb 17, 2026EPS Estimate
-0.59Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.41
Shares Outstanding23,590,025
10 Day Avg. Volume589,716
30 Day Avg. Volume657,064
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$45.00Price Target Upside651.25% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical TrialsSteady progress across both late-stage programs, with CYB004 Phase 2a enrollment complete and top-line data expected in the first quarter, and CYB003 advancing through the Phase 3 PARADIGM program under Breakthrough Therapy Designation.
Financial StabilityCybin raised $175 million through a registered direct financing, combined with cash of $83.8 million at the end of F2Q26, Cybin's runway extends into 2027, through multiple key data readouts.
Leadership And ManagementThe board is actively searching for a new CEO following a leadership transition, reinforcing management’s focus on operational rigor and execution as the company approaches a significant clinical year.
Bears Say
Financial ProjectionsThe increased share count from the recent financing, normalization of expenses in the model, and fine-tuning the expected CYB003 and CYB004 launches resulted in a revised $55 price target from $150.
Stock Price TargetThe updated model includes a reduced price target from $70 to $45, mainly due to dilution from the recent capital raise.
Cybin News
CYBN FAQ
What was Cybin’s price range in the past 12 months?
Cybin lowest stock price was $4.81 and its highest was $10.80 in the past 12 months.
What is Cybin’s market cap?
Cybin’s market cap is $1.39M.
When is Cybin’s upcoming earnings report date?
Cybin’s upcoming earnings report date is Feb 17, 2026 which is in 71 days.
How were Cybin’s earnings last quarter?
Cybin released its earnings results on Nov 13, 2025. The company reported -$1.408 earnings per share for the quarter, missing the consensus estimate of -$1.052 by -$0.356.
Is Cybin overvalued?
According to Wall Street analysts Cybin’s price is currently Undervalued.
Does Cybin pay dividends?
Cybin does not currently pay dividends.
What is Cybin’s EPS estimate?
Cybin’s EPS estimate is -0.59.
How many shares outstanding does Cybin have?
Cybin has 23,590,025 shares outstanding.
What happened to Cybin’s price movement after its last earnings report?
Cybin reported an EPS of -$1.408 in its last earnings report, missing expectations of -$1.052. Following the earnings report the stock price went down -8.05%.
Which hedge fund is a major shareholder of Cybin?
Currently, no hedge funds are holding shares in CYBN
Company Description
Cybin
Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a phenethylamine derivative to treat neuroinflammation. It has also developed EMBARK, a psychedelic-assisted psychotherapy. The company is headquartered in Toronto, Canada.
CYBN Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflects a company making significant progress in advancing its clinical programs and strengthening its financial position, despite facing challenges such as leadership transition and increased expenses. The overall sentiment is balanced, with solid achievements in clinical and operational fronts but offset by financial and leadership concerns.View all CYBN earnings summariesCYBN Stock 12 Month Forecast
Average Price Target
$45.00
▲(651.25% Upside)